Vascular Biogenics Ltd. (VBLT) Trading Down 4.5%
Vascular Biogenics Ltd. (NASDAQ:VBLT)’s share price was down 4.5% during trading on Thursday . The company traded as low as $4.15 and last traded at $4.20, with a volume of 235,307 shares traded. The stock had previously closed at $4.40.
A number of equities analysts have recently commented on VBLT shares. Roth Capital reissued a “buy” rating and set a $22.00 price target on shares of Vascular Biogenics in a report on Thursday, June 9th. Chardan Capital reissued a “buy” rating on shares of Vascular Biogenics in a report on Tuesday, June 7th. Piper Jaffray Cos. reissued a “buy” rating and set a $14.00 price target on shares of Vascular Biogenics in a report on Tuesday, June 7th. HC Wainwright started coverage on Vascular Biogenics in a report on Tuesday, June 28th. They set a “buy” rating and a $11.00 price target for the company. Finally, Zacks Investment Research raised Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Wednesday, June 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $16.50.
The stock’s market capitalization is $96.42 million. The stock has a 50-day moving average price of $4.16 and a 200 day moving average price of $3.68.
Vascular Biogenics (NASDAQ:VBLT) last announced its quarterly earnings data on Friday, May 13th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, meeting the consensus estimate of ($0.21). Equities analysts forecast that Vascular Biogenics Ltd. will post ($0.82) earnings per share for the current year.
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.